TAK-259

• Description:

  TAK-259 is an orally active and selective α1D adrenoceptor (α1D-AR) antagonist with a Ki value of 1.1 nM. TAK-259 inhibits excessive contraction of bladder smooth muscle and prolongs voiding intervals. TAK-259 is promising for research of urinary system diseases[1][2].

• UNSPSC:

  12352005

• Hazard Statement:

  H302-H315-H319-H335

• Target:

  Adrenergic Receptor

• Related Pathways:

  GPCR/G Protein; Neuronal Signaling

• Field of Research:

  Endocrinology

• Smiles:

  O=C(C1=CC(Cl)=CN(CC2=CC(Cl)=CC=C2S(=O)(C)=O)C1=N)N

• Molecular Formula:

  C14H13Cl2N3O3S

• Molecular Weight:

  374.24

• Precautions:

  P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P362+P364-P405-P501

• References & Citations:

  [1]Sato A, et al. Structure determination, synthesis, and biological evaluation of a metabolite of the selective α1D adrenoceptor antagonist TAK-259[J]. Tetrahedron, 2016, 72 (41) : 6334-6339.|[2]Sakauchi N, et al. Discovery of 5-Chloro-1- (5-chloro-2- (methylsulfonyl) benzyl) -2-imino-1,2-dihydropyridine-3-carboxamide (TAK-259) as a Novel, Selective, and Orally Active α1D Adrenoceptor Antagonist with Antiurinary Frequency Effects: Reducing Human Ether-a-go-go-Related Gene (hERG) Liabilities. J Med Chem. 2016 Apr 14;59 (7) :2989-3002.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound2

• Clinical Information:

  No Development Reported

• Isoform:

  α adrenergic receptor

• CAS Number:

  1192348-73-4